Cargando…

Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain

PURPOSE: Proper monitoring and management of chemotherapy-induced nausea and vomiting (CINV) with antiemetics is crucial for cancer patients. This study aimed to evaluate the use of antiemetics for the treatment of highly emetogenic chemotherapy (HEC) including carboplatin in the real-world setting...

Descripción completa

Detalles Bibliográficos
Autores principales: Escobar Álvarez, Y., De Castro Carpeño, J., Bell, D., Drago, A., Franceschetti, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8390393/
https://www.ncbi.nlm.nih.gov/pubmed/33956310
http://dx.doi.org/10.1007/s12094-021-02623-8
_version_ 1783743078291472384
author Escobar Álvarez, Y.
De Castro Carpeño, J.
Bell, D.
Drago, A.
Franceschetti, A.
author_facet Escobar Álvarez, Y.
De Castro Carpeño, J.
Bell, D.
Drago, A.
Franceschetti, A.
author_sort Escobar Álvarez, Y.
collection PubMed
description PURPOSE: Proper monitoring and management of chemotherapy-induced nausea and vomiting (CINV) with antiemetics is crucial for cancer patients. This study aimed to evaluate the use of antiemetics for the treatment of highly emetogenic chemotherapy (HEC) including carboplatin in the real-world setting in Spain. METHODS: A representative panel of cancer specialists was asked to collect information about the antiemetic treatments provided to patients receiving chemotherapy. Records formed part of the Global Oncology Monitor(©) database (Ipsos Healthcare, London, UK). Chemotherapy data were extrapolated using Ipsos Healthcare’s projection methodology. RESULTS: A total of 73 experts were finally included. Data from 9519 patients, estimated to be representative of 202,084 patients, were collected. HEC (and carboplatin-based chemotherapy) was administered to 73,118 (36%) patients, cisplatin-based therapy being the most frequent treatment (n = 34,649, 47.38%). Neurokinin-1 receptor antagonists (NK(1)RAs) alone or in combination were used as prophylaxis for CINV in 14,762 (20%) patients, while the combination of NK(1)RA with 5-hydroxytryptamine-3 receptor antagonist (5-HT(3)RAs) and dexamethasone as recommended by the international guidelines was used in 5849 (8%) patients only. No antiemetic prophylaxis was administered to 8.46% of the patients receiving HEC (n = 6189). Physicians classified cisplatin-, anthracycline-cyclophosphamide (AC-), and carboplatin-based regimens as HEC in 63%, 22% and 4% of the cases, respectively. CONCLUSIONS: The use of NK(1)RA-containing regimens for CINV prevention in patients treated with HEC was less than expected, suggesting poor adherence to international antiemetic guidelines.
format Online
Article
Text
id pubmed-8390393
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-83903932021-09-14 Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain Escobar Álvarez, Y. De Castro Carpeño, J. Bell, D. Drago, A. Franceschetti, A. Clin Transl Oncol Research Article PURPOSE: Proper monitoring and management of chemotherapy-induced nausea and vomiting (CINV) with antiemetics is crucial for cancer patients. This study aimed to evaluate the use of antiemetics for the treatment of highly emetogenic chemotherapy (HEC) including carboplatin in the real-world setting in Spain. METHODS: A representative panel of cancer specialists was asked to collect information about the antiemetic treatments provided to patients receiving chemotherapy. Records formed part of the Global Oncology Monitor(©) database (Ipsos Healthcare, London, UK). Chemotherapy data were extrapolated using Ipsos Healthcare’s projection methodology. RESULTS: A total of 73 experts were finally included. Data from 9519 patients, estimated to be representative of 202,084 patients, were collected. HEC (and carboplatin-based chemotherapy) was administered to 73,118 (36%) patients, cisplatin-based therapy being the most frequent treatment (n = 34,649, 47.38%). Neurokinin-1 receptor antagonists (NK(1)RAs) alone or in combination were used as prophylaxis for CINV in 14,762 (20%) patients, while the combination of NK(1)RA with 5-hydroxytryptamine-3 receptor antagonist (5-HT(3)RAs) and dexamethasone as recommended by the international guidelines was used in 5849 (8%) patients only. No antiemetic prophylaxis was administered to 8.46% of the patients receiving HEC (n = 6189). Physicians classified cisplatin-, anthracycline-cyclophosphamide (AC-), and carboplatin-based regimens as HEC in 63%, 22% and 4% of the cases, respectively. CONCLUSIONS: The use of NK(1)RA-containing regimens for CINV prevention in patients treated with HEC was less than expected, suggesting poor adherence to international antiemetic guidelines. Springer International Publishing 2021-05-06 2021 /pmc/articles/PMC8390393/ /pubmed/33956310 http://dx.doi.org/10.1007/s12094-021-02623-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Escobar Álvarez, Y.
De Castro Carpeño, J.
Bell, D.
Drago, A.
Franceschetti, A.
Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain
title Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain
title_full Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain
title_fullStr Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain
title_full_unstemmed Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain
title_short Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain
title_sort prevention of chemotherapy-induced nausea and vomiting in the real-world setting in spain
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8390393/
https://www.ncbi.nlm.nih.gov/pubmed/33956310
http://dx.doi.org/10.1007/s12094-021-02623-8
work_keys_str_mv AT escobaralvarezy preventionofchemotherapyinducednauseaandvomitingintherealworldsettinginspain
AT decastrocarpenoj preventionofchemotherapyinducednauseaandvomitingintherealworldsettinginspain
AT belld preventionofchemotherapyinducednauseaandvomitingintherealworldsettinginspain
AT dragoa preventionofchemotherapyinducednauseaandvomitingintherealworldsettinginspain
AT franceschettia preventionofchemotherapyinducednauseaandvomitingintherealworldsettinginspain